NCT02966912

Magnesium Supplementation for Primary Prevention of Heart Failure in Obesity

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Providence VA Medical Center · Federal
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to investigate whether nutritional supplementation with magnesium can improve cardiovascular structure and function in participants with obesity - with a long-term goal of preventing clinical heart failure. Specifically, in a randomized open-label pilot study, we will assess whether dietary Magnesium (Mg) supplementation (versus no supplementation) for 24 weeks in obese patients will improve left ventricular (LV) mass.

Detailed description

The investigators propose a 24-week therapeutic trial involving 40 participants with obesity from the Providence VA Medical Center without clinical heart failure. 20 participants will be treated with 400 mg of Magnesium Oxide twice daily, while 20 participants will receive no treatment. The trial tests the hypothesis that oral Mg supplementation will improve: LV structure (by LV mass, steatosis, and ECV), LV function (systolic and diastolic), vascular health (systolic blood pressure and aortic pulse wave velocity) and visceral adiposity.

Conditions

• Obesity

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	400 mg of Magnesium Oxide twice daily for 24 weeks
OTHER	Open label (none)

Timeline

• Start date: 2016-11-01
• Primary completion: 2019-03-01
• Completion: 2019-09-01
• First posted: 2016-11-17
• Last updated: 2023-02-24

Locations

1 site across 1 country: United States